References
- Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–528.
- Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
- Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71(suppl 2):i2–45.
- Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–864.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
- Arthur AB, Klinkhoff AV, Teufel A. Safety of self-injection of gold and methotrexate. J Rheumatol. 1999;26:302–305.
- Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2.
- Enbrel® (etanercept). Full prescribing information [package insert]. Thousand Oaks (CA): Immunex Corporation; 2013.
- Allen E, Seaman C. Likert scales and data analyses. Qual Prog. [cited 2016 Oct 27]. Available from: http://asq.org/quality-progress/2007/07/statistics/likert-scales-and-data-analyses.html.
- Wong-Baker FACES Foundation. Wong-Baker Faces® pain rating scale. [cited 2015 Sep 10] Available from: http://wongbakerfaces.org/
- Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996;29:602–608.
- Stanford Patient Education Research Center. Stanford HAQ 8-item disability scale. [cited 2010 Jan 13]. Available from: http://patienteducation.stanford.edu/research/haq8.html.
- Schulze-Koops H, Giacomelli R, Samborski W, et al. Factors influencing the patient evaluation of injection experience with the smartJect autoinjector in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:201–208.
- Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–493.
- Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–1090.
- Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28:1619–1629.
- Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10:301–307.
- Muller-Ladner U, Flipo RM, Vincendon P, et al. Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis. Z Rheumatol. 2012;71:890–899.